ELYM - Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
2024-06-28 13:58:26 ET
Summary
- Results from Eliem Therapeutics, Inc.'s phase 1b study, using TNT119 for the treatment of patients with membranous nephropathy, expected by the end of 2024.
- It is expected that the global membranous nephropathy treatment market could reach $328.4 million by 2034.
- Two other large market indications that can be targeted using TNT119 are systemic lupus erythematosus and immune thrombocytopenia.
- Acquisition of Tenet Medicines and $120 million private placement agreement provide funding for operations into 2027, with cash on hand at $220 million.
Eliem Therapeutics, Inc. ( ELYM ) is gearing up to report additional results from its phase 1b study using TNT119 for the treatment of patients with membranous nephropathy [MN]. It already released some prior data from this study, and now it is going to release additional results by the end of 2024, which could possibly unlock further shareholder value....
Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value